Back to top

oncology-screening: Archive

Zacks Equity Research

BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?

BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.

AMGNPositive Net Change SRPTPositive Net Change BGNENegative Net Change CRSPNegative Net Change

Zacks Equity Research

Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted

Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.

BMYPositive Net Change MRKPositive Net Change PBYIPositive Net Change

Zacks Equity Research

AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag

AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.

AZNPositive Net Change PBYIPositive Net Change DERMPositive Net Change CTMXNegative Net Change